The combination of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes offers additive benefits for cardiovascular risk reduction, glycaemic control, weight management, and blood pressure, without introducing new safety concerns beyond the established profiles of each drug class. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.